Sulsal Haque

502 total citations
15 papers, 346 citations indexed

About

Sulsal Haque is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Otorhinolaryngology. According to data from OpenAlex, Sulsal Haque has authored 15 papers receiving a total of 346 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 5 papers in Otorhinolaryngology. Recurrent topics in Sulsal Haque's work include Head and Neck Cancer Studies (5 papers), Lung Cancer Treatments and Mutations (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Sulsal Haque is often cited by papers focused on Head and Neck Cancer Studies (5 papers), Lung Cancer Treatments and Mutations (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Sulsal Haque collaborates with scholars based in United States, Cayman Islands and Italy. Sulsal Haque's co-authors include John C. Morris, Olugbenga Olowokure, Trisha M. Wise‐Draper, Roman Jandarov, Mario Medvedovic, Damaris Kuhnell, Wen Niu, Vidhya Karivedu, Jacob M. Hendershot and Jacek Biesiada and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Stroke.

In The Last Decade

Sulsal Haque

14 papers receiving 345 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sulsal Haque United States 6 168 148 89 62 58 15 346
Manu Prasad Israel 12 183 1.1× 146 1.0× 83 0.9× 59 1.0× 54 0.9× 27 359
Yuansheng Duan China 13 231 1.4× 109 0.7× 123 1.4× 46 0.7× 42 0.7× 33 402
Francesca Sparano Italy 9 113 0.7× 219 1.5× 65 0.7× 103 1.7× 78 1.3× 19 369
Renba Liang China 10 212 1.3× 145 1.0× 150 1.7× 53 0.9× 57 1.0× 14 400
Francesca Consoli Italy 9 92 0.5× 209 1.4× 128 1.4× 72 1.2× 56 1.0× 37 367
Zhenqian Wu China 11 169 1.0× 178 1.2× 98 1.1× 118 1.9× 72 1.2× 16 368
Guo‐He Lin China 10 118 0.7× 266 1.8× 82 0.9× 75 1.2× 103 1.8× 37 427
Tarannum Ferdous Japan 12 150 0.9× 171 1.2× 70 0.8× 116 1.9× 28 0.5× 34 385
Yuxiang Chen China 10 166 1.0× 154 1.0× 132 1.5× 42 0.7× 58 1.0× 26 367
Shinji Mikami Japan 9 108 0.6× 147 1.0× 77 0.9× 32 0.5× 15 0.3× 20 305

Countries citing papers authored by Sulsal Haque

Since Specialization
Citations

This map shows the geographic impact of Sulsal Haque's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sulsal Haque with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sulsal Haque more than expected).

Fields of papers citing papers by Sulsal Haque

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sulsal Haque. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sulsal Haque. The network helps show where Sulsal Haque may publish in the future.

Co-authorship network of co-authors of Sulsal Haque

This figure shows the co-authorship network connecting the top 25 collaborators of Sulsal Haque. A scholar is included among the top collaborators of Sulsal Haque based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sulsal Haque. Sulsal Haque is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Leddon, Jennifer L., Sulsal Haque, Shuchi Gulati, et al.. (2021). Adjuvant nivolumab following salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy: A single-arm phase II multi-institutional study.. Journal of Clinical Oncology. 39(15_suppl). 6031–6031. 2 indexed citations
2.
3.
Karivedu, Vidhya, Rishi Agarwal, Sulsal Haque, et al.. (2019). Lymphopenia as a predictor of survival in chemoradiation-treated stage III non-small-cell lung cancer (NSCLC): a multi-center retrospective analysis. Journal of Radiation Oncology. 8(2). 163–170. 1 indexed citations
4.
5.
Haque, Sulsal, Liang Niu, Damaris Kuhnell, et al.. (2018). Differential expression and prognostic value of long non‐coding RNA in HPV‐negative head and neck squamous cell carcinoma. Head & Neck. 40(7). 1555–1564. 30 indexed citations
6.
Sadraei, Nooshin Hashemi, Yan Feng, Lingling Du, et al.. (2018). High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer. Lung Cancer. 126. 48–54. 5 indexed citations
7.
Haque, Sulsal & John C. Morris. (2017). Transforming growth factor-β: A therapeutic target for cancer. Human Vaccines & Immunotherapeutics. 13(8). 1741–1750. 212 indexed citations
8.
Haque, Sulsal, et al.. (2017). Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy. Drug Design Development and Therapy. Volume 11. 2537–2549. 6 indexed citations
9.
Haque, Sulsal, et al.. (2016). Practice Patterns in Newly Diagnosed Multiple Myeloma in the Prospective Observational Commpass Trial. Blood. 128(22). 4502–4502. 2 indexed citations
10.
Ying, Binwu, Michelle Mierzwa, Ehsan Malek, et al.. (2015). Lymphopenia as a predictor of survival in chemoradiation (CRT)-treated stage III non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 33(15_suppl). e18513–e18513. 8 indexed citations
11.
Haque, Sulsal, et al.. (2015). Pulmonary metastases in pancreatic cancer, is there a survival influence?. PubMed. 6(3). E48–51. 45 indexed citations
12.
Haque, Sulsal, Mathew J. Reeves, Heidi Sucharew, et al.. (2012). Abstract 30: The Frailty Index: A Novel Predictor Of Stroke Outcomes. Stroke. 43(suppl_1). 1 indexed citations
13.
Haque, Sulsal, Mathew J. Reeves, Susan Ofner, et al.. (2012). Abstract 2275: Frailty Independently Predicts Poor Outcomes But Not Quality Of Care: An Analysis Of VA Ischemic Stroke Patients. Stroke. 43(suppl_1). 1 indexed citations
14.
Fury, Matthew G., Eric J. Sherman, Kenneth M. Algazy, et al.. (2011). A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m2 for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC).. Journal of Clinical Oncology. 29(15_suppl). 5563–5563. 3 indexed citations
15.
Pfister, David G., Sulsal Haque, Hilda E. Stambuk, et al.. (2010). A phase II study of pemetrexed (P) plus gemcitabine (G) in patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC).. Journal of Clinical Oncology. 28(15_suppl). 5554–5554. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Manu Prasad Breakdown of academic impact, for papers by Yuansheng Duan Breakdown of academic impact, for papers by Francesca Sparano Breakdown of academic impact, for papers by Renba Liang Breakdown of academic impact, for papers by Francesca Consoli Breakdown of academic impact, for papers by Zhenqian Wu Breakdown of academic impact, for papers by Guo‐He Lin Breakdown of academic impact, for papers by Tarannum Ferdous Breakdown of academic impact, for papers by Yuxiang Chen Breakdown of academic impact, for papers by Shinji Mikami
Rankless by CCL
2026